Italy suspends use of AstraZeneca COVID vaccine nationwide

ROME: Italy on Monday suspended the use of the AstraZeneca COVID-19 vaccine, making it the latest European country to put the product on hold following reports of recipients falling ill.

The announcement came shortly after Germany took the same step, and followed the seizure of hundreds of thousands of doses of the vaccine by Italian prosecutors in the northern region of Piedmont.

The Italian medicines authority AIFA said it was taking the decision as a “precautionary and temporary measure” pending rulings by the European Medicines Agency.

AstraZeneca’s shot was among the first and cheapest to be developed and launched at volume since the coronavirus was first identified in central China at the end of 2019 and is set to be the mainstay of vaccination programmes in much of the developing world. The virus has killed more than 2.7 million people.

Thailand became the first country outside Europe to delay rolling out the vaccine on Friday, when its political leaders were due to have the first shots, but the government said on Monday they would receive the AstraZeneca vaccine on Tuesday.

Indonesia, however, said it would delay administering the shot due to the reports of blood clots among some recipients in Europe and would await a review from the WHO.

The WHO had already said there was no indication the events were caused by the vaccination, a view also expressed by the European Medicines Agency (EMA), which said the number of reported blood clots was no higher than seen in the general population.

The handful of reported side-effects in Europe have upset vaccination programmes already under pressure over slow rollouts and vaccine scepticism in some countries.

The Netherlands said on Monday it had seen 10 cases of possible noteworthy adverse side-effects from the AstraZeneca vaccine, hours after the government put its vaccination programme on hold following reports of potential side-effects in other countries.

Denmark reported “highly unusual” symptoms in a 60-year-old citizen who died from a blood clot after receiving the vaccine, the same phrase used on Saturday by Norway about three people under the age of 50 it said were being treated in hospital.

“It was an unusual course of illness around the death that made the Danish Medicines Agency react,” the agency said in a statement late on Sunday.

AstraZeneca said earlier it had conducted a review covering more than 17 million people vaccinated in the European Union and the UK which had shown no evidence of an increased risk of blood clots.

Leave a Comment